<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82784">
  <stage>Registered</stage>
  <submitdate>23/04/2008</submitdate>
  <approvaldate>28/04/2008</approvaldate>
  <actrnumber>ACTRN12608000223336</actrnumber>
  <trial_identification>
    <studytitle>Prognostic factors affecting outcome of vascular growth factor inhibitor bevacizumab (Avastin) therapy and reactivation of the disease in the wet age related degeneration of the eye.</studytitle>
    <scientifictitle>The effect of anterior chamber protein concentration, gene polymorphisms and complement factors on visual acuity, contrast sensitivity, microperimetry, optical coherence tomography (OCT) findings and need of repeated drug injections in patients with exudative age related macular degeneration treated with intravitreal bevacizumab (Avastin) injection therapy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Age related macular degeneration of the eye (AMD)</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bevacizumab 25 mg/ml, Avastin, Roche, 0,05 ml, 1,25 mg injected intravitreally once a month for two years when exudative AMD lesion is diagnosed to be active.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual acuity tested with charts used in Early Treatment Diabetic Retinopathy Study (ETDRS Charts)</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Retinal thickness measured with Oti Spectral optical coherence tomography/scanning laser ophthalmoscope (OCT/SLO)</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total number of drug injections needed to treat the exudative AMD lesion</outcome>
      <timepoint>At 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Central macular sensitivity tested with Oti Spectral optical coherence tomography/scanning laser ophthalmoscope (OCT/SLO) microperimetry</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Contrast sensitivity tested with Pelli-Robson Contrast Sensitivity Charts</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anterior chamber flare levels measured with Kowa Laser Flare Meter FM-500, Kowa Company Ltd., Nagoya, Japan</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Microperimetry results, measured with the spectral domain OCT/scanning laser ophthalmoscope, Spectral OCT/SLO, Opko/OTI, Miami, FL, USA.</outcome>
      <timepoint>At baseline and at 1, 2, 3 and 4 weeks, then monthly for 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with classic, predominantly classic, minimally classic or occult type of exudative AMD and visual acuity at least 20/200.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior treatment of exudative macular degeneration, prior intraocular surgery other than uncomplicated cataract surgery, uncomplicated cataract surgery within one year, diabetes, intraocular tumors, other retinal diseases or retinal vascular occlusions, prior retinal panphotocoagulation, prior significant intraocular inflammation or infection and poor co-operation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/05/2008</anticipatedstartdate>
    <actualstartdate>7/05/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/04/2010</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/04/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsingin ja Uudenmaan sairaanhoitopiiri</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ilkka Immonen</primarysponsorname>
    <primarysponsoraddress>HYKS Silmaklinikka
PL 220
00029 HUS</primarysponsoraddress>
    <primarysponsorcountry>Finland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Helsinki University Central Hospital Research Foundation</fundingname>
      <fundingaddress>HUS yhtymahallinto 
Tutkimus- ja opetusryhma
PL 100
00029 HUS</fundingaddress>
      <fundingcountry>Finland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Asta Hautamaki</sponsorname>
      <sponsoraddress>HYKS Silmaklinikka
PL 220
00029 HUS</sponsoraddress>
      <sponsorcountry>Finland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to find factors that may affect the efficacy of the intraocular vascular growth factor inhibitor treatment in patients with the wet form of age related degeneration of the eye. Factors studied are specific genetic markers, proteins involved in immune response and protein concentration in the anterior chamber of the eye.</summary>
    <trialwebsite />
    <publication>Publications:

Hautamäki A, Luoma A, Immonen I. Anterior Chamber Flare during Bevacizumab Treatment in Eyes with Exudative Age-Related Macular Degeneration. Retina 2016;36:2183-2190.

Hautamäki A, Seitsonen S, Holopainen J, Moilanen J, Kivioja J, Onkamo P, Järvelä I, Immonen I. The genetic variant rs4073 A/T of the Interleukin-8 promoter region is associated with the earlier onset of exudative age-related macular degeneration. Acta Ophthalmologica 2015;93(8):726-733.

Hautamäki, A., Kivioja, J., Seitsonen, S., Savolainen, E-R., Liinamaa, MJ., Luoma, A., Järvelä, I., Immonen, I. The IL-8, VEGF, and CFH Polymorphisms and Bevacizumab in Age-related Macular Degeneration. Ophthalmology 2014;121(4):973-973.

Hautamäki, A., Oikkonen, J., Onkamo, P., Immonen, I. Correlation between components of newly diagnosed exudative age-related macular degeneration lesion and focal retinal sensitivity. Acta Ophthalmologica, 2014;92(1):51-58.

Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E-R., Savolainen, MJ., Liinamaa, MJ., Seitsonen, S., Onkamo, P., Järvelä, I., Immonen, I. Interleukin-8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina 2013;33(9):1815-1827.


Presentations:

Immonen, IJ., Hautamäki, A. Anterior chamber flare during a prospective 2-year study of pro re nata (PRN) treatment of exudative age-related macular degeneration (AMD) with intravitreal bevacizumab injections. Poster presentation, ARVO 2015, Annual meeting of the Association for Research in Vision and Ophthalmology, Denver, CO, USA.

Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E-R., Savolainen, MJ., Liinamaa, MJ., Seitsonen, S., Onkamo, P., Järvelä, I., Luoma, A., Immonen, I. The effects of interleukin-8, VEGF and CFH polymorphisms on the long-term response to bevacizumab therapy in exudative age-related macular degeneration. Oral presentation, EVER 2013, Congress of the European Association for Vision and Eye Research, Nice, France.

Immonen, I., Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E-R., Savolainen, MJ., Liinamaa, MJ., Seitsonen, S., Onkamo, P., Järvelä, I. Interleukin-8 promoter polymorphism is associated with the initial repose to bevacizumab in AMD treatment. Poster presentation, EVER 2013, Congress of the European Association for Vision and Eye Research, Nice, France.

Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E-R., Savolainen, MJ., Liinamaa, MJ., Seitsonen, S., Onkamo, P., Järvelä, I., Immonen, I. The association of IL-8 promoter polymorphism -251 A/T to the initial bevacizumab treatment response in exudative AMD. Oral presentation, Euretina 2013, Congress of the European Society of Retina Specialists, Hamburg, Germany.

Immonen, IJ., Hautamäki, A., Oikkonen, J., Onkamo, P. Correlation Between Components Of Newly Diagnosed Exudative Age-related Macular Degeneration Lesion And Focal Retinal Sensitivity In Oct-microperimetry. Poster presentation, ARVO 2012, Annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA.

Hautamäki, A., Immonen, I. Correlation between components of exudative age-related macular degeneration lesion and local retinal sensitivity. Poster presentation, NOK 2010, Nordic Congress of Ophthalmology, Reykjavik, Iceland. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NKL NSK:n eettinen toimikunta</ethicname>
      <ethicaddress>HYKS, NKL NSK eettinen tmk
PL 220
00029 HUS</ethicaddress>
      <ethicapprovaldate>10/01/2008</ethicapprovaldate>
      <hrec>Dnro 387/E9/07 HUS</hrec>
      <ethicsubmitdate />
      <ethiccountry>Finland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ilkka Immonen</name>
      <address>HYKS Silmaklinikka
PL 220
00029 HUS</address>
      <phone>+358 9 471 73 167</phone>
      <fax />
      <email>ilkka.immonen@hus.fi</email>
      <country>Finland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Asta Hautamaki</name>
      <address>HYKS Silmaklinikka
PL 220
00029 HUS</address>
      <phone>+358 50 427 93 13</phone>
      <fax />
      <email>asta.hautamaki@hus.fi</email>
      <country>Finland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Asta Hautamaki</name>
      <address>HYKS Silmaklinikka
PL 220
00029 HUS</address>
      <phone>+358 50 427 93 13</phone>
      <fax />
      <email>asta.hautamaki@hus.fi</email>
      <country>Finland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Asta Hautamaki</name>
      <address>HYKS Silmaklinikka
PL 220
00029 HUS
Finland</address>
      <phone>+358 40 82 22 911</phone>
      <fax />
      <email>asta.hautamaki@hus.fi</email>
      <country>Finland</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>